Recent Updates
Recently added Catalysts
LXRX Positive Sentiment

Lexicon Pharmaceuticals to Participate in Three Upcoming March 2026 Investor Conferences

Wednesday, March 4, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Lexicon Pharmaceuticals announced its participation in three investor conferences in March 2026. The company will engage in a fireside chat at the Leerink Partners Global Healthcare Conference and hold 1x1 meetings at the Jefferies Biotech on the Beach Summit and Barclays Global Healthcare Conference. This involvement highlights Lexicon's commitment to investor relations and showcases its ongoing development efforts.
Price reaction · baseline $1.61 (2026-03-03 close) · hit pre-market · 1 other LXRX headline(s) in the window, move may be shared
day 0 close · peak
+1.2%

Market Sentiment Analysis

POSITIVE FACTORS

  • Lexicon Pharmaceuticals is actively engaging with investors.
  • Participation in multiple high-profile conferences demonstrates confidence.
  • The company has a diverse pipeline addressing significant health issues.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+111%
120-day peak, hindsight
Typical move
11%
average across 13 past catalysts
Cash runway
~61 mo
Minimal dilution risk
Lead asset
Sotagliflozin
Phase 3 · Type 1 Diabetes Mellitus

Full Press Release Details

THE WOODLANDS, Texas, March 03, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Company management will participate in an upcoming fireside chat at the2026 Leerink Partners Global Healthcare Conferencein Miami on Wednesday, March 11, at 10:00 a.m.
Lexicon will also be participating in 1x1 investor meetings at the2026 Jefferies Biotech on the Beach Summit, March 10–11, and at theBarclays 28th Global Healthcare Conference,March 10-12.
A live recording and replay of the Leerink fireside chat can be accessed via the Events page of the Company’s website athttps://investors.lexpharma.com/.
About Lexicon PharmaceuticalsLexicon is a biopharmaceutical company with a mission of pioneering medicines that transform patients’ lives. Lexicon has a pipeline of drug candidates in discovery, preclinical, and clinical development in neuropathic pain, hypertrophic cardiomyopathy (HCM), obesity and metabolic disorders, and other cardiometabolic indications. For additional information, please visitwww.lexpharma.com.

For Investor and Media Inquiries:Lisa DeFrancescoLexicon Pharmaceuticals, Inc.lexinvest@lexpharma.com

Frequently Asked Questions

What conferences will Lexicon Pharmaceuticals attend?

Lexicon will participate in the Leerink Partners Global Healthcare Conference, Jefferies Biotech on the Beach Summit, and Barclays Global Healthcare Conference.

When is the Leerink Partners Global Healthcare Conference?

The Leerink Partners Global Healthcare Conference is scheduled for March 11, 2026.

How can I access the fireside chat recording?

The live recording and replay of the fireside chat can be accessed on Lexicon's Events page.

What is Lexicon Pharmaceuticals focused on?

Lexicon focuses on developing medicines for neuropathic pain, hypertrophic cardiomyopathy, obesity, and other metabolic disorders.

ShareAdd on Google
Tags: LXRX Viatris Investor Conferences Healthcare Lexicon Pharmaceuticals investor conferences healthcare conference biotech summit
Last updated: Mar 4, 2026

Biotech snapshot

Cash runway
$191M liquidity · $3M/mo burn
~61 mo
Minimal dilution risk
Lead asset
SotagliflozinPhase 3
Type 1 Diabetes Mellitus →

Catalyst track record

+111%
best trade around LXRX's most recent catalyst

Peak hindsight return over a 120-day window, across 13 tracked FDA/PDUFA catalysts for LXRX.

See every catalyst's timing & PoA →